Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity.
OBJECTIVE
To determine the prevalence of measles (rubeola) immunity in a group of HIV-1-infected adults and to examine predictors of measles seronegativity in this population.


METHODS
County hospital outpatient clinic and public-health department early HIV intervention clinic.


METHODS
A total of 262 HIV-infected adults presenting to outpatient clinics between September 1990 and January 1991.


METHODS
Patients were screened for the presence of measles immunoglobulin G antibody, as measured by an enzyme-linked immunosorbent assay (ELISA). Pertinent clinical and immunologic information was recorded. Univariate and multivariate analyses were performed to identify possible risk factors for measles seronegativity.


METHODS
Measles seronegativity, as defined by a lack of detectable antibody (ELISA predicted index value < 1.0).


RESULTS
Thirteen (5%) patients lacked serologic evidence of immunity. Risk factors for measles seronegativity included year of birth in 1957 or later, Caucasian (non-Hispanic) race and oral hairy leukoplakia. Factors associated with progressive HIV disease (other than hairy leukoplakia) were not associated with a lack of existing immunity.


CONCLUSIONS
A high prevalence (95%) of measles antibody was found in this large group of HIV-infected adults. Young, white individuals born in 1957 or later were at the greatest risk for measles seronegativity, but declining immunity due to progressive HIV infection did not appear to be associated with a lack of antibody. Self-reported histories of measles infection or immunization were not reliable predictors of measles immunity.
Kemper
C A
CA
Department of Medicine, Stanford University School of Medicine, California.
Zolopa
A R
AR
Hamilton
J R
JR
Fenstersheib
M
M
Bhatia
G
G
Deresinski
S C
SC
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D015497:HIV-1; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008457:Measles / Q000150:complications / Q000276:immunology / Q000517:prevention & control; D008459:Measles virus / Q000276:immunology*; D008875:Middle Aged
D000914:Antibodies, Viral; D007074:Immunoglobulin G